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Abstract: The 26S proteasome is the central proteolytic machinery of the ubiquitin proteasome
system (UPS), which is involved in the degradation of ubiquitinated protein substrates. Recently,
UPS inhibition has been shown to be a key factor in fatty liver graft preservation during organ
cold storage using University of Wisconsin solution (UW) and Institute Georges Lopez (IGL-1)
solutions. However, the merits of IGL-1 and histidine-tryptophan-ketoglutarate (HTK) solutions
for fatty liver preservation have not been compared. Fatty liver grafts from obese Zücker rats were
preserved for 24 h at 4 ◦C. Aspartate aminotransferase and alanine aminotransferase (AST/ALT),
glutamate dehydrogenase (GLDH), ATP, adenosine monophosphate protein kinase (AMPK), e-NOS,
proteasome activity and liver polyubiquitinated proteins were determined. IGL-1 solution prevented
ATP breakdown during cold-storage preservation of steatotic livers to a greater extent than HTK
solution. There were concomitant increases in AMPK activation, e-NOS (endothelial NOS (NO
synthase)) expression and UPS inhibition. UPS activity is closely related to the composition of the
solution used to preserve the organ. IGL-1 solution provided significantly better protection against
ischemia-reperfusion for cold-stored fatty liver grafts than HTK solution. The effect is exerted through
the activation of the protective AMPK signaling pathway, an increase in e-NOS expression and a
dysregulation of the UPS.
Keywords: ubiquitin proteasome system; cold ischemic injury; fatty liver preservation; IGL-1; HTK;
ATP; AMPK and nitric oxide
1. Introduction
Misfolded or damaged proteins are degraded by cells without the non-specific destruction
of essential cell constituents [1]. In eukaryotic cells, the proteasome controls protein degradation.
Proteins that will be degraded are firstly labelled by ubiquitin in an energy-requiring process
named the ubiquitin proteasome system (UPS) [2]. The UPS is identified as a highly specialized
degradation machinery compartmentalized by different structural and functional proteins before
efficient removal [1]. The 26S proteasome is composed of a core 20S particle, in which proteins are
digested to short peptides, and one or two 19S regulatory particles that are responsible for substrate
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recognition and transport into the core particle [3]. These particles are known to participate in
degradation and folding of many regulatory proteins that are involved in cell cycle, metabolism,
inflammation and growth, and in other processes including ischemia-reperfusion injury (IRI) [4,5].
IRI is inherent to liver transplantation [6,7]. After organ recovery from the donor, the liver graft
is stored in an organ preservation solution in hypothermic conditions in order to maintain graft
viability until transplantation. The deprivation of oxygen and nutrients to the organ during this cold
storage leads to a severe ATP energy-metabolism breakdown, which is accompanied by concomitant
activation of protective cell-signaling mechanisms such as adenosine monophosphate protein kinase
(AMPK) [8–10]. AMPK acts as a metabolic fuel gauge to restore cellular and whole-body energy
balance. Enhancement of AMPK activity also induces e-NOS (endothelial NOS (NO synthase)) activity
and thus NO production, which has been widely demonstrated to prevent endothelial cell damage [5].
Cold ischemic storage involves an inherent injury in the preserved grafts, which is partially mitigated
by the use of organ preservation solution. The most-used preservation solution in liver transplantation is
University of Wisconsin solution (UW), considered the gold standard for transplantation of abdominal
organs [11]. Other solutions such as Celsior, histidine-tryptophan-ketoglutarate (HTK) and Institute
Georges Lopez (IGL-1) are also widely used. Briefly, UW contains hydroxyethyl starch (HES) as oncotic
agent, lactobionate and raffinose (for edema prevention), the antioxidants allopurinol and reduced
glutathione, and high potassium and low sodium concentrations [12]. IGL-1 is identical to UW, except
that HES is replaced by polyethylene glycol 35 (PEG 35) and has inverted sodium/potassium ratio, as
shown in Table 1 [13]. For their part, HTK and Celsior have no oncotic agent.
Table 1. Comparison between histidine-tryptophan-ketoglutarate (HTK) and Institute Georges Lopez
(IGL-1) preservation solutions components.







Buffers (m·mol/L) Antioxydants (m·mol/L)
Diphosphate 25
Glutathione 3Histidine 180
Histidine-HO 18 Allopurinol 1Tryptophan 2
Impermeants (m·mol/L ) Precursors (m·mol/L )
Raffinose 30 Adenosine 5
Lactobionic acid 100 Ketoglutarate 1
Mannitol 30 pH 7.4 7.2
Osmolarity 290 310
Recent investigations have shown that the UPS is involved in cold liver IRI [14]. Majetschak’s
group reported that ATP activates the 26S proteasome during cold ischemia and increases myocardial
injury, and that proteasome inhibition may be a promising tool for improving heart preservation
strategies [15]. Following on from that study, our group further demonstrated that the use of UPS
inhibitors such as MG132 and bortezomib protected liver graft against cold IRI when used at low doses
as additives in preservation solutions and in experimental liver transplantation [16,17]. However, the
research into the role of the UPS in liver-graft preservation is scarce and is limited to the use of UW
and IGL solutions; much less is known about the use of other preservation solutions such as HTK.
With this in mind, the present study focuses on the relevance of the UPS dysregulation associated with
liver ischemic injury which occurs when fatty liver grafts are preserved in HTK or IGL-1 solutions,
and aims to identify and discuss a variety of protective preservation mechanisms.
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2. Results
First we evaluated hepatic injury according to transaminase and glutamate dehydrogenase
(GLDH) levels, as shown in Figure 1. The release of transaminases and GLDH after 24 h of cold ischemia
was more-effectively prevented in IGL-1 solution-preserved fatty livers than in HTK-preserved livers.
This was consistent with the histological findings shown in Figure 2. Controls showed grade II to III of
fatty infiltration, with hepatocyte integrity maintenance that contrasted with IGL-1 and HTK groups
that revealed the most-severe histological changes. HTK group showed severe cellular damage and
disintegration of hepatic cords when compared to IGL-1 (Figure 2).
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Figure 1. Liver injury (A) and mitochondrial damage (B) in fatty liver grafts preserved in Institute 
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Figure 2. Histology hematoxylin–eosin staining. Photomicrographs of livers at 20× magnification: (A) 
Control group showing normal hepatic architecture with macro- and micro-vesicular fatty 
infiltration; (B) HTK group. Extensive areas of cell dissociation, cell swelling and disintegration of 
hepatic architecture are seen (C) IGL group. Well-preserved lobular architecture with minimal 
sinusoidal dilatation and cell swelling are observed. 
Figure 1. Liver injury (A) and mitochondrial damage (B) in fatty liver grafts preserved in Institute
Georges Lopez (IGL-1) and histidine-tryptophan-ketoglutarate (HTK) vs. SHAM. Results are expressed
as mean ± SEM (n = 6). * p < 0.05 represent significant differences vs. SHAM and # p < 0.05 vs. IGL-1.
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These results were consistent with the higher prevention of mitochondrial damage, determined
by GLDH activity levels, in livers preserved in IGL-1 solution than in livers preserved in HTK.
The histologic study of control steatotic livers showed grade II to III of fatty infiltration, with hepatocyte
integrity maintenance. The other groups conserved fatty infiltration. The most severe changes in
histology were observed in the HTK group, showing severe cellular damage and disintegration of
hepatic cords. Improved histological characteristics were noted in the IGL-1 group, where moderate
cellular damage was seen (Figure 2). Our results indicate that IGL-1 solution was more efficient than
HTK solution in reducing hepatic injury and functionality.
We next determined the energy-metabolism breakdown and UPS activity in liver grafts preserved
in the two solutions. Livers preserved in IGL-1 revealed higher ATP levels than those preserved in
HTK (Figure 3A). This better conservation of ATP levels was associated with a stronger inhibition of
UPS activity (measured as chymotryptic-like activity) in fatty liver grafts preserved in IGL-1 solution
than in those preserved in HTK after 24 h of cold preservation (Figure 3B). These results are consistent
with the higher levels of 20S and polyubiquitinated proteins found in liver grafts preserved in HTK
than in grafts preserved in IGL-1 solution (Figure 4). No differences were found in 19S.
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Finally, in cold-stored livers, we determined the activation of AMPK and e-NOS, two
cyto-protective factors induced during ischemic conditions [10,18]. Both tissue cyto-protective markers
were expressed more in steatotic livers preserved in IGL-1 solution than in livers preserved in HTK
solution, showing a similar profiling pattern (Figure 5). Therefore, IGL-1 provides better protection of
fatty livers against the deleterious effects of cold IRI than does HTK.
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3. Discussion
This paper studied the relevance of the UPS in cold-preserved fatty liver graft injury, comparing
two frequently used preservation solutions: IGL-1 and HTK. Our data demonstrated that IGL-1
preservation solution reduced fatty liver injury associated with cold ischemia to a greater extent than
HTK solution.
During cold storage, liver grafts are deprived of oxygen and nutrient supply. This stops
energetic metabolism, depletes ATP levels and renders the organ more susceptible to IRI [11].
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The process is exacerbated in steatotic livers as a consequence of abnormal fat accumulation in
hepatic sinusoids, leading to a severe obstruction of hepatic flow with substantial alterations in liver
microcirculation [19,20]. In our study, the cold storage of fatty liver grafts in IGL-1 solution significantly
prevented hepatocellular and mitochondrial injury in comparison with HTK solution. ATP levels were
also better conserved in the fatty livers undergoing IGL-1 solution cold storage.
The AMPK signaling pathway is activated during stress conditions such as exercise, starvation,
hypoxia and ischemia, when energy levels are swiftly depleted. Upon energy depletion, AMPK triggers
ATP-producing pathways while inhibiting ATP-consuming pathways, hence balancing the metabolic
processes towards cellular energy homeostasis [8]. We found a significant activation of AMPK in
fatty livers preserved in IGL-1 solution but not in those preserved in HTK solution. This result was
consistent with the increased ATP levels found in the fatty livers preserved in IGL-1.
The direct regulatory effects of ATP on the 26S proteasome have already been described, since
ATP is required for 26S proteasome formation and stabilization [21]. It has been shown that both
in cell extracts and in proteasomes purified from different sources, ATP depletion can release the
19S regulatory particle from the 20S core, while the addition of ATP can reverse the process [22,23].
These results suggest that under conditions in which the levels of ATP may be compromised, the
proteasome activity is likely to be due to the 20S activity [24,25]. More interestingly, in addition
to the ATP requirement for the 19S and 20S assembly, proteasome activity increases when the
ATP concentration is below physiological levels [15]. This implies that the pathological conditions
associated with a decrease in cellular ATP, such as liver cold ischemia, may increase proteasome
activity. Accordingly, in our study, the chymotryptic-like activity of 26S and 20S showed that both
were significantly increased in fatty livers cold-preserved with HTK solution, precisely the ones with
the lowest ATP levels. Furthermore, in this group, the levels of polyubiquitinated proteins were also
significantly increased compared with the IGL-1 group. Our findings suggest that IGL-1 provides
better protection for fatty livers against the deleterious effects of cold IRI than does HTK (Figure 6).
A key observation in a previous study by our group was the fact that the benefits of
IGL-1 solution are associated with the generation of nitric oxide (NO), a potent vasodilator
agent which counterbalances the exacerbated microcirculation alterations present in steatotic liver
grafts [18,19,26,27]. We have also reported that AMPK activation induces NO synthesis, thus protecting
against hepatic injury in both steatotic and non-steatotic liver transplantation [28]. Accordingly, we
found a significantly higher expression of e-NOS in fatty livers preserved in IGL-1 solution than in
those preserved in HTK.Int. J. Mol. Sci. 2017, 18, 2287  7 of 10 
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4. Material and Methods
4.1. Animals
Homozygous (obese (Ob)) Zücker rats aged 16–18 weeks from Charles River (France) were used.
All animals had free access to water and dry food. All animals were used in accordance with protocols
approved on 14 July 2016 (483116). The study was performed in accordance with the European Union
Directive 2010/63/EU for animal experiments and approved by the Ethics Committees for Animal
Experimentation of the University of Barcelona (Directive 396/12). Animals were randomly distributed
into groups as described below.
4.2. Experimental Groups
Experimental groups were as follows:
• Group 1 (SHAM; n = 6): Animals underwent transverse laparotomy and received silk ligatures in
the right suprarenal vein, diaphragmatic vein, and hepatic artery.
• Group 2 (IGL-1; n = 6): After organ recovery, the livers were flushed with 40 mL of IGL-1 solution
and stored in IGL-1 preservation solution for 24 h at 4 ◦C.
• Group 3 (HTK; n = 6): After organ recovery, the livers were flushed with 100 mL of HTK solution
(2.5 times more than IGL-1) and stored in HTK solution for 24 h at 4 ◦C.
After cold storage, the liver specimens in IGL-1 and HTK solutions were washed with Ringer
lactate solution (20 mL) and samples were taken from the flush. Liver samples were then stored at
−80 ◦C for the subsequent biochemical determinations.
4.3. Biochemical Determinations
4.3.1. Proteasome Chymotryptic-Like Activity Assay
In order to evaluate the proteasome activity, we determined the proteasome chymotryptic-like (β5)
ATP-dependent (26S) and non-ATP-dependent (20S) activity using the substrate N-Suc-Leu-Leu-Val-
Tyr-aminomethylcoumarin from ENZO Life Science (Alcobendas, Madrid), as previously reported [16].
Liver cell lysates were prepared by homogenization in 50 mM Tris, 1 mM EDTA, 5 mM MgCl2, 150 mM
NaCl, and 1 mM DTT, pH 7.5. The samples were then centrifuged at 12,000× g for 15 min (4 ◦C) and the
supernatants were collected. To analyze the proteasome activity of liver homogenates (25 µg/sample),
the fluorescent substrate Suc-LLVY-AMC 100 µM for β5 was used. All the assays were carried out
in a total volume of 100 µL. The ATP-dependent 26S was measured in the presence of 0.1 mM ATP.
Each assay was conducted in the absence and presence of the specific proteasome inhibitor epoxomicin
(Peptides International) at a final concentration of 20 µM.
The cleavage products 7-amino-4-methycoumarin (AMC) were measured by fluorimetric techniques
(excitation/emission 380/460 nm) according to the supplier’s instructions using a microplate fluorometer
(Tecan Infinite Microplate Reader).
4.3.2. Transaminase Assay
Hepatic injury was evaluated by alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) levels using commercial kits from RAL (Barcelona, Spain), as previously reported [18]. Briefly,
100 µL of effluent washout liquid or perfusate was added to 1 mL of the substrate provided by the
commercial kit, and then transaminase activity was measured at 340 nm with a UV spectrometer
and calculated following the supplier’s instructions. Results were normalized using a commercial
calibrator (Biocal, RAL).
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4.4. Histology
Liver samples were fixed in 10% neutral buffered formalin and embedded in Paraplast, and 5-µm
sections were stained with hema-toxylin and eosin according to standard procedures. Histologic
evaluation was graded semiquantitatively from 0 (no damage) to 4 (severe cellular damage, such as
vacuolization, cell dissociation, cell swelling and disintegration of hepatic architecture).
4.5. Glutamate Dehydrogenase Activity
Mitochondrial damage was measured as glutamate dehydrogenase activity (GLDH), as previously
reported [18], with GLDH Randox Laboratories Ltd. commercial kit (Antrim, UK), using eluate as
sample and quantifying the decrease in absorbance at 340 nm according to the manufacturer’s protocol.
4.6. Energy Metabolism (ATP Breakdown)
The determination of ATP in liver samples homogenated in a perchloric acid solution was
performed using the ATP assay kit for fluorimetry (Sigma Aldrich ATP colorimetric/fluorimetric
assay kit, Madrid, Spain). The ATP concentration was determined by the phosphorylation of glycerol,
which is a detectable product for the fluorimeter (excitation/emission 535 nm/587 nm) at 37 ◦C
and proportional to the amount of ATP in the sample. Energy breakdown during cold storage was
measured through the changes in ATP levels, as previously described [29].
4.7. Western-Blotting Analysis
Liver tissue was homogenized in HEPES buffer, and proteins were separated by sodium dodecyl
sulfate polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride or nitrocellulose
membranes. Membranes were immunoblotted overnight at 4 ◦C with antibodies against ubiquitin
(U5379, Sigma-Aldrich, Madrid, Spain), Rpt1, 20S core subunits (α5/α7, β1, β5, β5i, and β7)
(BML-PW 8895 and BML-PW8825, respectively, ENZO Life Sciences, Madrid, Spain), AMPK (#ab80039)
and p-AMPK (#133448) (Abcam, Cambridge, UK). Antibodies against e-NOS/NOS (#610297, BD
Biosciences, Madrid, Spain) and P-eNOS (#9571, Cell Signalling, Leiden, The Netherlands) were also
used. Membranes were washed afterwards and incubated 1 h at room temperature with secondary
antibody. Detection was performed with anti-IgG-HRP (Santa Cruz Biotechnology, Inc., Heidelberg,
Germany). Signals were detected by enhanced chemiluminescence and quantified by scanning
GS800 calibrated densitometer (Biorad, Madrid, Spain). Both β-actin and α-tubulin were used as
loading controls.
4.8. Statistics
Data are expressed as mean± standard error, and were compared statistically by variance analysis,
followed by the Student–Newman–Keuls test using GraphPad Prism version 4.02 for Windows
(GraphPad Prism software; Accession data: 17 May 2004). p < 0.05 was considered significant.
5. Conclusions
In conclusion, the data reported here show that IGL-1 preservation solution performs better than
HTK preservation solution for fatty liver graft cold storage. The effects of this preservation may be
directly related with the oncotic agent, PEG 35, contained in the IGL-1 solution, since its presence is
one of the main differences between the solutions. More studies are now required in order to explore
this possibility further. The protective effects of IGL-1 solution are associated, at least in part, with the
activation of AMPK, stabilization of the cell ATP content and high e-NOS expression. This leads to the
inhibition of the UPS activity and the ubiquitination of proteins which, in the final analysis, reduce the
cold ischemia-associated damage in fatty livers.
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